Pioneering studies in 2005 revealed that concurrent loss of both PARP1 activity and BRCA1/2-mediated homologous recombination (HR) resulted in catastrophic DNA damage and selective tumor cell death, which have fundamentally reshaped strategies for targeted cancer therapies. This evidence concerns the gene PARP1 and neoplasm.